Salvage Radiotherapy for Recurrent Prostate Cancer

Outcome of post‐prostatectomy radiotherapy in one institution

“…These patients may therefore have achieved some gain from postoperative RT, in spite of the presence of biochemical progression or systemic relapse(Table 4).Strict monitoring of toxicity is important in determining the benefit of RT in this group of patients who are at a high risk of relapse after RT. As reported in other more recent publications, the morbidity associated with this treatment in this study is low in part because the advent of 3-D RT planning and improvement in the surgical techniques [1][2][3][4][5][6][7][10][11][12][13]. Allowance must be made for the short median follow up of 19.5 months.…”

“…The majority of patients presented with Gleason score 7 adenocarcinoma of the prostate cancer as reported by others (Table 2). 1,3,12,13 The median follow up for the entire group was 0.27 0.57 †Shown in Figure 2. Statistically significant P-values are in bold.…”

Salvage radiotherapy for biochemical recurrence after radical prostatectomy

“…However, compared to other reports the present patients were relatively free from unfavourable pathological features such as a RP Gleason score of ≥ 8 (two men) or seminal vesicle invasion (one). Notably, the PSA level before RT was a significant prognostic variable, supporting the ‘earlier the better’ approach to salvage RT [25] even in low PSA ranges (<0.5 ng/mL in 92% of patients). Inevitably there is some bias in our patient selection for salvage RT.…”

Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional survey study of the JROSG

“…[11] report in their retrospective study of 86 patients that favorable outcomes were obtained at doses of 64.8 Gy and above. Some research [12–14] suggests that ADT may control tumors at lower doses than salvage radiotherapy, but Ost et al [15] describe favorable outcomes with higher doses. They reported that 225 patients with SVI, EPE and positive margins achieved 7-year bRFS rates of 84% and clinical RFS rates of 88% with doses ≥69 Gy, suggesting the effects of increasing doses beyond 68–69 Gy in an adjuvant setting as well.…”